Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

NCT05054478 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Leukemia

Interventions

DRUG: Daratumumab

Sponsor

Assistance Publique - Hôpitaux de Paris